AAMU
IOVA icon

Amundi Asset Management US’s Iovance Biotherapeutics IOVA Stock Holding History

Amundi Asset Management US’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$241K Hold
7,600
– – ﹤0.01% 1450
2020
Q4 		$353K Hold
7,600
– – ﹤0.01% 1350
2020
Q3 		$250K Buy
7,600
+200
+3% +$6.13K ﹤0.01% 1358
2020
Q2 		$203K Hold
7,400
– – ﹤0.01% 1383
2020
Q1 		$222K Buy
+7,400
New +$196K ﹤0.01% 1316

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Amundi Asset Management US's IOVA Position: Q1 2021 in Review

Amundi Asset Management US held its Iovance Biotherapeutics (IOVA) position steady in Q1 2021 at 7,600 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Amundi Asset Management US first reported a position in IOVA in Q1 2020 and has held it in 5 quarters since. The position peaked at $353K in Q4 2020. 251 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Amundi Asset Management US held 7,600 shares of Iovance Biotherapeutics worth $241K as of Q1 2021.
  • Amundi Asset Management US left its Iovance Biotherapeutics share count unchanged in Q1 2021.
  • Iovance Biotherapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1450 holding.
  • Amundi Asset Management US first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 5 quarters since.
  • Amundi Asset Management US's Iovance Biotherapeutics position peaked at $353K in Q4 2020.
  • 251 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.